Global Diabetic Neuropathy Market 2014-2018: Key Vendors are Eli Lilly and Co, Janssen Pharmaceuticals and Pfizer Inc.

News provided by

Research and Markets

08 Aug, 2014, 13:31 GMT

DUBLIN, Aug. 8, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Diabetic Neuropathy Market 2014-2018" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

R&D activities in the Diabetic Neuropathy sector are growing in terms of an increase in the number of mergers and acquisitions. Big pharmaceutical companies take up later-stage products from small companies, where efficacy has already been demonstrated, thereby cutting down initial R&D expenditure.

For instance, in March 2013, BioDelivery Sciences International Inc. in-licensed a patented topical formulation of clonidine gel from Arcion Therapeutics Inc. for the treatment of indications including diabetic neuropathy. In July 2013, Acorda Therapeutics acquired two candidates for neuropathic pain including NP-1998, a topical capsaicin solution, from NeurogesX Inc. In-licensing by big pharmaceutical companies, in turn, diverts funds to be spent by the smaller companies on marketing and commercialization to R&D development.

According to the report, the Global Diabetic Neuropathy market is driven by several factors, of which the increase in the global diabetic population is one of the major drivers. The incidence and prevalence rate of diabetes is growing continuously, mainly because of the adoption of a sedentary form of life and unhealthy eating habits accompanied by increased life expectancy.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Geographical Segmentation

08. Buying Criteria

09. Market Growth Drivers

10. Drivers and their Impact

11. Market Challenges

12. Impact of Drivers and Challenges

13. Market Trends

14. Trends and their Impact

15. Vendor Landscape

16. Key Vendor Analysis

17. Pipeline Analysis

18. Other Reports in this Series

Companies Mentioned:

  • Eli Lilly and Co
  • Janssen Pharmaceuticals
  • Pfizer
  • Actavis
  • Cephalon
  • MEDA Pharma GmbH & Co

For more information visit http://www.researchandmarkets.com/research/q8x6s6/global_diabetic

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net